{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:42:26Z","timestamp":1793508146329,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To efficiently implement plasma and cerebrospinal fluid (CSF) biomarkers for staging and prognosis of Alzheimer disease (AD), we must understand their dynamics across disease progression. We analyzed participants from the Swedish BioFINDER-2 study with mass spectrometry measurements of plasma and CSF tau species, including eMTBR-tau243\/MTBR-tau243 and phosphorylation occupancies (%p-tau). Disease duration was estimated using A\u03b2-PET and tau-PET with the SILA algorithm. Bootstrapped LOESS models showed that %p-tau217 changes earliest, increasing just before A\u03b2-PET positivity. Other p-tau species changed later, with smaller dynamic ranges and earlier ceiling effects. %p-tau205 and MTBR-tau243 changes aligned with tau-PET positivity onset, while MTBR-tau243\u2014especially plasma eMTBR-tau243\u2014tracked cortical tau burden in later stages. Non-phosphorylated mid-region tau may serve as a late-stage biomarker. Taken together, concurrent assessments of plasma or CSF %p-tau217, %p-tau205, and (e)MTBR-tau243 provides information about different biological events in the disease cascade, which can benefit clinical trials and patient management in clinical practice.<\/jats:p>","DOI":"10.1038\/s41467-026-71732-1","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:26:30Z","timestamp":1775744790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer\u2019s disease continuum"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6263-1762","authenticated-orcid":false,"given":"Lyduine E.","family":"Collij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5210-9230","authenticated-orcid":false,"given":"Gemma","family":"Salvad\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-2614","authenticated-orcid":false,"given":"Kanta","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4937-2860","authenticated-orcid":false,"given":"Nicolas R.","family":"Barth\u00e9lemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8856-1352","authenticated-orcid":false,"given":"Tobey J.","family":"Betthauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0112","authenticated-orcid":false,"given":"Ruben","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1680-1465","authenticated-orcid":false,"given":"Suzanne E.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-7477","authenticated-orcid":false,"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-8378","authenticated-orcid":false,"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-7724","authenticated-orcid":false,"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-1702","authenticated-orcid":false,"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"71732_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"71732_CR2","doi-asserted-by":"crossref","unstructured":"Rafii, M. S. et al. The AHEAD 3-45 Study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. 19, 1227\u20131233 (2023).","DOI":"10.1002\/alz.12748"},{"key":"71732_CR3","doi-asserted-by":"crossref","unstructured":"Jack, C.R. Jr. et al. Revised criteria for the diagnosis and staging of Alzheimer\u2019s disease. Nat. Med. 30, 2121\u20132124 (2024).","DOI":"10.1038\/s41591-024-02988-7"},{"key":"71732_CR4","doi-asserted-by":"crossref","unstructured":"Boustani, M. et al. Estimating the economically justifiable price of limited-duration treatment with donanemab for early symptomatic Alzheimer\u2019s disease in the United States. Neurol. Ther. 13, 1641\u20131659 (2024).","DOI":"10.1007\/s40120-024-00649-y"},{"key":"71732_CR5","doi-asserted-by":"crossref","unstructured":"Groot, C. et al. Tau positron emission tomography for predicting dementia in individuals with mild cognitive impairment. JAMA Neurol. 81, 845\u2013856 (2024).","DOI":"10.1001\/jamaneurol.2024.1612"},{"key":"71732_CR6","doi-asserted-by":"crossref","unstructured":"Ossenkoppele, R. et al. Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials. Nat. Aging 5, 883\u2013896 (2025).","DOI":"10.1038\/s43587-025-00835-z"},{"key":"71732_CR7","doi-asserted-by":"crossref","unstructured":"Collij, L. E. et al. Centiloid recommendations for clinical context-of-use from the AMYPAD consortium. Alzheimers Dement. 20, 9037\u20139048 (2024).","DOI":"10.1002\/alz.14336"},{"key":"71732_CR8","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens, P. et al. Alzheimer\u2019s disease.  Lancet 397, 1577\u20131590 (2021).","journal-title":"Lancet"},{"key":"71732_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s43587-024-00599-y","volume":"4","author":"G Salvad\u00f3","year":"2024","unstructured":"Salvad\u00f3, G. et al. Disease staging of Alzheimer\u2019s disease using a CSF-based biomarker model. Nat. Aging 4, 694\u2013708 (2024).","journal-title":"Nat. Aging"},{"key":"71732_CR10","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat. Med. 29, 1954\u20131963 (2023).","journal-title":"Nat. Med."},{"key":"71732_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","volume":"3","author":"NR Barth\u00e9lemy","year":"2023","unstructured":"Barth\u00e9lemy, N. R. et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease. Nat. Aging 3, 391\u2013401 (2023).","journal-title":"Nat. Aging"},{"key":"71732_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3233\/JAD-210677","volume":"85","author":"NR Barthelemy","year":"2022","unstructured":"Barthelemy, N. R. et al. Site-specific cerebrospinal fluid tau hyperphosphorylation in response to Alzheimer\u2019s disease brain pathology: not all tau phospho-sites are hyperphosphorylated. J. Alzheimers Dis. 85, 415\u2013429 (2022).","journal-title":"J. Alzheimers Dis."},{"key":"71732_CR13","first-page":"1","volume":"12","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy, N. R. et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer\u2019s disease and PET amyloid-positive patient identification. Alzheimer\u2019s. Res. Ther. 12, 1\u201311 (2020).","journal-title":"Alzheimer\u2019s. Res. Ther."},{"key":"71732_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat. Commun. 11, 1683 (2020).","journal-title":"Nat. Commun."},{"key":"71732_CR15","doi-asserted-by":"publisher","first-page":"e1681","DOI":"10.1212\/WNL.0000000000012727","volume":"97","author":"A Leuzy","year":"2021","unstructured":"Leuzy, A. et al. Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 assays. Neurology 97, e1681\u2013e1694 (2021).","journal-title":"Neurology"},{"key":"71732_CR16","doi-asserted-by":"crossref","unstructured":"Ashton, N. J. et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease. EBioMedicine 76, 103836 (2022).","DOI":"10.1016\/j.ebiom.2022.103836"},{"key":"71732_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2024","unstructured":"Mattsson-Carlgren, N. et al. Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies. JAMA Neurol. 81, 69\u201378 (2024).","journal-title":"JAMA Neurol."},{"key":"71732_CR18","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat. Med. 28, 2555\u20132562 (2022).","journal-title":"Nat. Med."},{"key":"71732_CR19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"71732_CR20","doi-asserted-by":"crossref","unstructured":"Kanta, H. et al. Plasma MTBR-tau243 identifies tau tangle pathology in Alzheimer\u2019s disease. Nat. Med. 31, 2044\u20132053 (2025).","DOI":"10.1038\/s41591-025-03617-7"},{"key":"71732_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat. Med. 26, 398\u2013407 (2020).","journal-title":"Nat. Med."},{"key":"71732_CR22","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1093\/brain\/awac213","volume":"145","author":"TJ Betthauser","year":"2022","unstructured":"Betthauser, T. J. et al. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain 145, 4065\u20134079 (2022).","journal-title":"Brain"},{"key":"71732_CR23","doi-asserted-by":"crossref","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Timing of changes in Alzheimer\u2019s disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508\u2013523 (2025).","DOI":"10.1002\/ana.27285"},{"key":"71732_CR24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ana.26891","volume":"95","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Timing of biomarker changes in sporadic Alzheimer\u2019s disease in estimated years from symptom onset. Ann. Neurol. 95, 951\u2013965 (2024).","journal-title":"Ann. Neurol."},{"key":"71732_CR25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy, A. et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 77, 955\u2013965 (2020).","journal-title":"JAMA Neurol."},{"key":"71732_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/brain\/awaa373","volume":"144","author":"K Horie","year":"2020","unstructured":"Horie, K., Barth\u00e9lemy, N. R., Sato, C. & Bateman, R. J. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease. Brain 144, 515\u2013527 (2020).","journal-title":"Brain"},{"key":"71732_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47971-5","volume":"15","author":"L Karlsson","year":"2024","unstructured":"Karlsson, L. et al. Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases. Nat. Commun. 15, 3676 (2024).","journal-title":"Nat. Commun."},{"key":"71732_CR28","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson, O., Blennow, K., Zetterberg, H. & Dage, J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat. Aging 3, 506\u2013519 (2023).","journal-title":"Nat. Aging"},{"key":"71732_CR29","doi-asserted-by":"publisher","first-page":"e70320","DOI":"10.1002\/alz.70320","volume":"21","author":"C Lane-Donovan","year":"2025","unstructured":"Lane-Donovan, C. et al. Tau phosphorylation at Alzheimer\u2019s disease biomarker sites impairs its cleavage by lysosomal proteases. Alzheimers Dement. 21, e70320 (2025).","journal-title":"Alzheimers Dement."},{"key":"71732_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 141, 709\u2013724 (2021).","journal-title":"Acta Neuropathol."},{"key":"71732_CR31","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801 (2022).","journal-title":"Nat. Med."},{"key":"71732_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13024-022-00586-0","volume":"17","author":"J Gobom","year":"2022","unstructured":"Gobom, J. et al. Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer\u2019s disease continuum. Mol. Neurodegener. 17, 81 (2022).","journal-title":"Mol. Neurodegener."},{"key":"71732_CR33","doi-asserted-by":"publisher","first-page":"6365","DOI":"10.1002\/alz.14132","volume":"20","author":"JK Wisch","year":"2024","unstructured":"Wisch, J. K. et al. Predicting continuous amyloid PET values with CSF tau phosphorylation occupancies. Alzheimers Dement. 20, 6365\u20136373 (2024).","journal-title":"Alzheimers Dement."},{"key":"71732_CR34","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson, N. et al. Independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer\u2019s disease. Brain 138, 772\u2013783 (2015).","journal-title":"Brain"},{"key":"71732_CR35","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1038\/s41380-022-01436-7","volume":"27","author":"R Cacciaglia","year":"2022","unstructured":"Cacciaglia, R. et al. Age, sex and APOE-\u03b54 modify the balance between soluble and fibrillar \u03b2-amyloid in non-demented individuals: topographical patterns across two independent cohorts. Mol. Psychiatry 27, 2010\u20132018 (2022).","journal-title":"Mol. Psychiatry"},{"key":"71732_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209419","volume":"103","author":"SE Mastenbroek","year":"2024","unstructured":"Mastenbroek, S. E. et al. Continuous \u03b2-amyloid CSF\/PET imbalance model to capture Alzheimer disease heterogeneity. Neurology 103, e209419 (2024).","journal-title":"Neurology"},{"key":"71732_CR37","doi-asserted-by":"crossref","unstructured":"Salvado, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. 15, EMMM202217123 (2023).","DOI":"10.15252\/emmm.202217123"},{"key":"71732_CR38","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jalz.2018.04.010","volume":"14","author":"RF Buckley","year":"2018","unstructured":"Buckley, R. F. et al. Sex, amyloid, and APOE \u03b54 and risk of cognitive decline in preclinical Alzheimer\u2019s disease: findings from three well-characterized cohorts. Alzheimers Dement. 14, 1193\u20131203 (2018).","journal-title":"Alzheimers Dement."},{"key":"71732_CR39","doi-asserted-by":"publisher","first-page":"e092486","DOI":"10.1002\/alz.092486","volume":"20","author":"W Coath","year":"2024","unstructured":"Coath, W. et al. Estimating age at A\u03b2 onset in the 1946 British birth cohort: exploring the influence of APOE \u025b4 carriership and sex. Alzheimers Dement. 20, e092486 (2024).","journal-title":"Alzheimers Dement."},{"key":"71732_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00259-019-04496-0","volume":"47","author":"R Smith","year":"2020","unstructured":"Smith, R. et al. Head-to-head comparison of tau positron emission tomography tracers [18F] flortaucipir and [18F] RO948. Eur. J. Nucl. Med. Mol. Imaging 47, 342\u2013354 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"71732_CR41","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel, J. W. et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat. Med. 27, 871\u2013881 (2021).","journal-title":"Nat. Med."},{"key":"71732_CR42","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C.R. Jr. et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"71732_CR43","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","volume":"29","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist, S. et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat. Med. 29, 1971\u20131978 (2023).","journal-title":"Nat. Med."},{"key":"71732_CR44","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, DSM-5 Task Force. Diagnostic and Statistical Manual of Mental Disorders, 5th edn (American Psychiatric Publishing, Inc., 2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"71732_CR45","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist, S. et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034\u20131042 (2021).","journal-title":"Nat. Med."},{"key":"71732_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk, W. E. et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 11, 1\u201315.e11-14 (2015).","journal-title":"Alzheimers Dement."},{"key":"71732_CR47","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.24711","volume":"80","author":"H Cho","year":"2016","unstructured":"Cho, H. et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann. Neurol. 80, 247\u2013258 (2016).","journal-title":"Ann. Neurol."},{"key":"71732_CR48","doi-asserted-by":"crossref","unstructured":"Wang, G. et al. The CentiMarker project: Standardizing quantitative Alzheimer\u2019s disease fluid biomarkers for biologic interpretation. Alzheimer\u2019s & Dementia 21, e14587 (2025).","DOI":"10.1002\/alz.14587"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71732-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:14:29Z","timestamp":1775747669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71732-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71732"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71732-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.E.C. has acquired research support from GE Healthcare and Springer Healthcare (paid by Eli Lilly), both paid to the institution. Dr. Collij is supported by the MSCA Postdoctoral fellowship (#101108819) and Alzheimer Association Research Fellowship (#23AARF-1029663) grants. G.S. has received speaker fees from Springer and Adium. G.S. received funding from the European Union\u2019s Horizon 2020 Research and Innovation Program under Marie Sklodowska-Curie action grant agreement number 101061836, an Alzheimer\u2019s Association Research Fellowship (AARF-22-972612), the Brightfocus Foundation (A2024007F), the Alzheimerfonden (AF-980942, AF-994514, AF-1012218), Greta och Johan Kocks research grants and travel grants from the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson\u2019s Disease) at Lund University. K.H. is an Eisai-sponsored voluntary research associate professor at Washington University and has received salary from Eisai. K.H., N.R.B., and R.J.B. may receive income based on technology (methods to detect MTBR-tau isoforms and use thereof) (PCT\/US2020\/046224) licensed by Washington University to C2N Diagnostics. K.H. and R.J.B. may receive income based on technology (anti-tau MTBR antibodies and methods to detect endogenously cleaved fragments of tau and uses thereof) (PCT\/US2023\/072738) licensed by Washington University to C2N Diagnostics. T.J.B. reported grants from the National Institutes of Health (NIH) during the conduct of the study and travel funding\/fellowship from Alzheimer\u2019s Association outside the submitted work. R.S. has received consultancy\/speaker fees from Eli Lilly, Novo Nordisk, Roche and Triolab. R.O. has received research funding from European Research Council, ZonMw, NWO, National Institute of Health, Alzheimer Association, Alzheimer Nederland, Stichting Dioraphte, Cure Alzheimer\u2019s Fund, Health Holland, ERA PerMed, Alzheimerfonden, and Hjarnfonden (all paid to the institutions). R.O. has received research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix, and Optina Diagnostics, and has given lectures in symposia sponsored by GE Healthcare. He is an advisory board member for Asceneuron and Bristol Myers Squibb. All the aforementioned have been paid to the institutions. He is an editorial board member of Alzheimer\u2019s Research & Therapy and the European Journal of Nuclear Medicine and Molecular Imaging. S.P. has acquired research support (for the institution) from Ki Elements\/ADDF and Avid. In the past 2 years, he has received consultancy\/speaker fees from BioArtic, Eisai, Lilly, Novo Nordisk, and Roche. S.E.S. has served on scientific advisory boards on biomarker testing and clinical care pathways for Eisai and Novo Nordisk and has received speaking fees for presentations on biomarker testing from Eisai, Eli Lilly, and Novo Nordisk. N.M.-C. has received funding from the Swedish Research Council (2021-02219), the Swedish Alzheimer Foundation (AF-994229), WASP and DDLS Joint call for research projects (WASP\/DDLS22-066), EU Join Programme Neurodegenerative Diseases (2019-03401), Family R\u00f6nnstr\u00f6m Foundation, Family Berg Foundation, the Swedish federal government under the ALF agreement (2022-Projekt0107), the Swedish Brain Foundation (FO2023-0163), Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Johan and Greta Kock Foundation, the Sk\u00e5ne University Hospital Foundation, Regionalt Forskningsst\u00f6d. He has received consultancy\/speaker fees from Biogen, Owkin, and Merck. R.J.B. is an unpaid scientific advisory board member of Roche and Biogen, and receives research funding from Avid Radiopharmaceuticals, Janssen, Roche or Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb, and Novartis. O.H. is an employee of Eli Lilly and Lund University. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3400"}}